Overview

This trial is active, not recruiting.

Condition kidney cancer
Treatments dactinomycin, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, melphalan, vincristine sulfate, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Phase phase 2
Sponsor Children's Cancer and Leukaemia Group
Start date May 2001
End date November 2008
Trial size 75 participants
Trial identifier NCT00025103, CCLG-UKWR, CDR0000068913, EU-20127

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: This phase II trial is studying how well chemotherapy followed by surgery and radiation therapy with or without stem cell transplant work in treating patients with relapsed or refractory Wilms' tumor or clear cell sarcoma of the kidney.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Primary Outcomes

Measure
Unified treatment strategy
time frame:
Improvement of current survival rates
time frame:
Efficacy and toxicity
time frame:
Prognostic variables
time frame:

Eligibility Criteria

Male or female participants up to 17 years old.

DISEASE CHARACTERISTICS: - Diagnosis of Wilms' tumor or clear cell sarcoma of the kidney, meeting 1 of the following criteria: - First relapse - Refractory (progression during first-line therapy) - Patients in second and subsequent relapses allowed if previously treated with vincristine, dactinomycin, and doxorubicin combination chemotherapy (VCR/DACT/DOX) - Metachronous tumors in the contralateral kidney allowed if previously treated with VCR/DACT/DOX - No rhabdoid tumor of the kidney - Previously treated on UK Wilms' tumor study PATIENT CHARACTERISTICS: Age: - Under 18 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - See Disease Characteristics

Additional Information

Official title Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK)
Description OBJECTIVES: - Determine survival rates of patients with relapsed or refractory Wilms' tumor or clear cell sarcoma of the kidney treated with chemotherapy followed by surgical resection and adjuvant radiotherapy with or without autologous stem cell rescue. - Determine the efficacy and toxicity of these regimens in these patients. - Determine prognostic variables in patients treated with these regimens. OUTLINE: Patients are assigned to one of three treatment regimens. - Regimen A (patients with initial stage I tumors previously treated with vincristine with or without dactinomycin with relapse at least 6 months after diagnosis): Patients receive vincristine IV once weekly on weeks 1-10 and then every 3 weeks during weeks 11-52, dactinomycin IV every 3 weeks during weeks 1-52, and doxorubicin IV over 6 hours every 3 weeks during weeks 1-34 (weeks 1-28 if pulmonary radiotherapy is planned). Patients undergo surgical resection and radiotherapy after 6 weeks of therapy. - Regimen B (patients with initial stage II tumors previously treated with vincristine and dactinomycin with relapse at least 6 months after diagnosis): Patients receive cyclophosphamide IV twice daily on days 1-2 and 22-23, etoposide IV over 1 hour on days 1-3, and doxorubicin IV over 6 hours on days 22 and 23. Treatment repeats every 42 days for a total of 4 courses. Patients undergo surgical resection and radiotherapy after 2 courses of chemotherapy. Patients not achieving complete response after 4 courses of chemotherapy undergo autologous bone marrow transplantation as in regimen C. - Regimen C (all other patients in first relapses OR with progression on first-line therapy OR in second or subsequent relapse previously treated on regimens A and B): Patients receive carboplatin IV over 1 hour on day 1, etoposide IV over 2 hours on days 1-3 and 22-24, and cyclophosphamide IV twice daily on days 22 and 23. Treatment repeats every 42 days for a total of 3 courses. Patients may undergo surgical resection prior to stem cell rescue. Beginning within 6 weeks after completion of chemotherapy, patients receive melphalan IV on day -1. Autologous peripheral blood stem cells or bone marrow is reinfused on day 0. Patients undergo radiotherapy after transplantation. Patients are followed every 8 weeks for 1 year, every 12 weeks for 1 year, and then every 6 months thereafter. PROJECTED ACCRUAL: Approximately 75 patients (25 for regimens A and B and 50 for regimen C) will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in August 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).